Testosterone depot injection in male hypogonadism: a critical appraisal

Testosterone compounds have been available for almost 70 years, but the pharmaceutical formulations have been less than ideal. Traditionally, injectable testosterone esters have been used for treatment, but they generate supranormal testosterone levels shortly after the 2- to 3-weekly injection interval and then testosterone levels decline very rapidly, becoming subnormal in the days before the next injection. The rapid fluctuations in plasma testosterone are subjectively experienced as disagreeable. Testosterone undecanoate is a new injectable testosterone preparation with a considerably better pharmacokinetic profile. After 2 initial injections with a 6-week interval, the following intervals between two injections are almost always 12-weeks, amounting eventually to a total of 4 injections per year. Plasma testosterone levels with this preparation are nearly always in the range of normal men, so are its metabolic products estradiol and dihydrotestosterone. The “roller coaster” effects of traditional parenteral testosterone injections are not apparent. It reverses the effects of hypogonadism on bone and muscle and metabolic parameters and on sexual functions. Its safety profile is excellent due to the continuous normalcy of plasma testosterone levels. No polycythemia has been observed, and no adverse effects on lipid profiles. Prostate safety parameters are well within reference limits. There was no impairment of uroflow. Testosterone undecanoate is a valuable contribution to the treatment options of androgen deficiency

Acute pancreatitis-induced by platinum compounds in patients with cancer: a review of the literature

The purpose of this review of the literature was to describe the relationship between use of platinum-based antineoplastics and development of acute pancreatitis in patients with cancer. A literature search was conducted using PubMed, Science Direct and Google scholar databases for articles published from 1985 to 2014. The headings and/or text words (platinum compounds), (acute pancreatitis-induced by platinum compounds), and (cisplatin, carboplatin, and oxaliplatin) were entered, and the search was limited to articles describing case reports in adults with cancer. A total of 12 cases were reported between 1985 and 2012; including three platinum compounds; cisplatin, carboplatin, and oxaliplatin. In conclusion, it is highly recommended to include baseline assessment for acute pancreatitis risk factors and to consider acute pancreatitis in the differential diagnosis of abdominal pain in patients who have received platinum-based chemotherapy

Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera)

Hepatitis C and polycythemia vera (PV) co-existence is not rare; it has been reported in the literature. Treatment with interferon (IFN) has been used to treat both conditions; however, the use of IFN in concomitant hepatitis C infection with PV and its outcome are rarely described in the literature. Here, we report a 56-years-old male patient with hepatitis C virus infection and PV, who was treated with IFN for his chronic hepatitis C, which resulted in significant improvement of HB as well as normalization of his bone marrow and eradication of the clone (Jak2 V617F)

A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of chronic myeloid leukemia (CML) since their approval. Although safe in general, TKIs carry concerns about cardiovascular adverse events. Hypertension, diabetes, and dyslipidemia are among the most common baseline comorbidities among CML patients. Guidelines for the management of the existing comorbidities or those related to TKI therapy are lacking. This paper will review hypertension, hyperglycemia and hyperlipidemia reported in CML patients or associated with TKI therapy and then propose a simple guide on their management

Production of Biodiesel from Jatropha curcas Seed Oil

This study was carried out to produce biodiesel from freshly harvested Jatropha curcas (J. curcas) seed oil. J. curcas seed oil has a high oil content (40%), the free fatty acids (FFA) range is (1.6-1.75%), peroxide value is 2.6 meq/kg, oil moisture content range is (0.2-0.3%) and saponification value range is (185-189) mg KOH/g oil. The main fatty acids are oleic 39.60 % and linoleic acids 34.64 %, unsaturated fatty acids in J. curcas oil are 75.54 wt%, while, saturated fatty acids are 24.46 wt%. The specifications of biodiesel produced are; Density is reduced from 0.9198 to 0.8810 g/cm3. The kinematic viscosity at 40 oC was reduced from 36.37 to 4.809 mm2/s, and the flash point is 187oC. Biodiesel produced complies with the requirements of the American Society for Testing and Materials (ASTM) standard D6751-09, and the Committee of Standardization in Europe (CEN) standard EN 14214 specifications

Esterification of High Free Fatty Acid Jatropha curcas Oil for Biodiesel Production

This study investigated the esterification of high free fatty acid (FFA) Jatropha curcas (J. curcas) seed oil (6.3 to14.6 %) to produce biodiesel using sulphuric acid with reaction parameters 1% H2SO4, 600 rpm at 60 oC and one hour reaction time. At methanol to oil ratio 3:1, FFAs were reduced to 4.73% with conversion 45%; at 6:1 methanol to oil ratio, FFAs were reduced to 2.31% with conversion 72%; at 7.5:1 methanol to oil ratio FFAs are decreased to less than 2% with conversion ≥85% and there is no considerable difference when increasing methanol to oil ratio to 9:1. Hence the optimum methanol to oil molar ratio is 7.5:1, moreover, the esterification process is not affected by the initial FFA

A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients

Background: Protein tyrosine phosphatase receptor gamma (PTPRG) is a ubiquitously expressed member of the protein tyrosine phosphatase family known to act as a tumor suppressor gene in many different neoplasms with mechanisms of inactivation including mutations and methylation of CpG islands in the promoter region. Although a critical role in human hematopoiesis and an oncosuppressor role in chronic myeloid leukemia (CML) have been reported, only one polyclonal antibody (named chPTPRG) has been described as capable of recognizing the native antigen of this phosphatase by flow cytometry. Protein biomarkers of CML have not yet found applications in the clinic, and in this study, we have analyzed a group of newly diagnosed CML patients before and after treatment. The aim of this work was to characterize and exploit a newly developed murine monoclonal antibody specific for the PTPRG extracellular domain (named TPγ B9-2) to better define PTPRG protein downregulation in CML patients. Methods: TPγ B9-2 specifically recognizes PTPRG (both human and murine) by flow cytometry, western blotting, immunoprecipitation, and immunohistochemistry. Results: Co-localization experiments performed with both anti-PTPRG antibodies identified the presence of isoforms and confirmed protein downregulation at diagnosis in the Philadelphia-positive myeloid lineage (including CD34+/CD38bright/dim cells). After effective tyrosine kinase inhibitor (TKI) treatment, its expression recovered in tandem with the return of Philadelphia-negative hematopoiesis. Of note, PTPRG mRNA levels remain unchanged in tyrosine kinase inhibitors (TKI) non-responder patients, confirming that downregulation selectively occurs in primary CML cells. Conclusions: The availability of this unique antibody permits its evaluation for clinical application including the support for diagnosis and follow-up of these disorders. Evaluation of PTPRG as a potential therapeutic target is also facilitated by the availability of a specific reagent capable to specifically detect its target in various experimental conditions

A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management

COVID-19 in a pregnant patient with beta-thalassemia major: A case report

Further studies are needed on this unique population to better manage them and increase their chances of normal pregnancy and fewer complications and more favorable outcomes